Enzymatica

On September 11, 2024, the subscription period for the Rights issue ended. The final outcome shows that the Rights issue was subscribed to 61.1 percent with subscription rights, 16.0 percent without subscription rights, and 22.9 percent according to guarantee commitments from large shareholders. The subscription price in the Rights issue was SEK 1.90 per share and the Company will receive proceeds amounting to around SEK 132 million before issue costs.

"The fully subscribed rights issue is a statement of strength from Enzymatica. Despite a strained financial situation on the financial market, the company is now infused with SEK 132 million, which lays a stable foundation for geographic expansion, further clinical studies, and more. It shows that there is strong faith in both the company and our products", said CEO Claus Egstrand.

Through the Rights Issue the share capital will increase from SEK 6,935,291 to 9,709,407.81. The total number of shares in the Company will increase from 173,382,220 to 242,735,108.

The allocation of shares subscribed without subscription rights has been carried out in accordance with the principles specified in the prospectus, which was prepared in connection with the Rights issue and published by the Company on August 26, 2024. Notification of allocation will be made through a settlement note sent to each subscriber. Allocated shares shall be paid for in accordance with the instructions on the settlement note. Nominee-registered shareholders will receive notification of allocation in accordance with instructions from their respective nominees. Only those who receive an allocation will be notified.

The last day for trading in paid-up subscribed shares (BTA) on Nasdaq First North Growth Market is expected to be September 23, 2024. The new shares are expected to be traded on Nasdaq First North Growth Market on or about September 30, 2024. The above is the final outcome of the Rights issue, thus no further press releases about the outcome of the Rights issue will be issued.

Advisors
Bergs Securities is the financial advisor and Setterwalls Law Firm is the legal advisor to Enzymatica in connection with the Rights issue.